Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Apatinib Dosing in Advanced Gastric Cancer
NCT03334591Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Oct 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), sponsored by The First Affiliated Hospital of USTC. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03334591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334591.